Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 20/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.45 |
| ▸ | CASP3 | P42574 | 11/20 | 0.39 |
| ▸ | CASP7 | P55210 | 11/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24461487 | 0.89 | CCNT1 (0.41) | CDK9CCNT1 | |
| SCHEMBL24461454 | 0.88 | CDK9 (0.44) | CDK9CCNT1CASP3CASP7 | |
| SCHEMBL24461455 | 0.88 | CCNT1 (0.38) | CDK9CCNT1 | |
| SCHEMBL24461407 | 0.85 | PBRM1 (0.37) | CDK9CCNT1 | |
| SCHEMBL24461477 | 0.84 | SMARCA2 (0.35) | CDK9CCNT1 | |
| SCHEMBL24461456 | 0.83 | PBRM1 (0.46) | CDK9CCNT1 | |
| SCHEMBL24461490 | 0.82 | SMARCA2 (0.39) | CDK9CCNT1 | |
| SCHEMBL24461343 | 0.82 | PBRM1 (0.38) | GSK3B | |
| SCHEMBL30552692 | 0.82 | PBRM1 (0.39) | — | |
| SCHEMBL24461424 | 0.81 | PBRM1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2022109426-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CDK9 2347/4885CCNT1 4446/4885CASP3 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.